In March 2023, just weeks after Anthropic released Claude — its powerful new large language model — IFORELS integrated the system with the open National Library of Medicine (NLM) evidence base to launch a sophisticated research synthesis bot. The tool extended the company’s established automation pattern from medical coding into a higher layer of clinical intelligence: automated literature review and evidence synthesis. Rather than focusing on consumer chat interfaces or general-purpose assistants, IFORELS directed Claude’s capabilities toward one of the most valuable public medical corpora in existence, creating a practical tool that accelerates the work of clinicians, researchers, and guideline developers.
The National Library of Medicine maintains an expansive, publicly available collection of biomedical literature, including millions of peer-reviewed studies, clinical trials, and systematic reviews. This corpus is vast, perpetually growing, and serves as the foundational reference for evidence-based medicine. Traditionally, synthesizing this information requires researchers or postdocs to pull dozens of papers, read them in detail, identify connections across studies, and flag contradictions or emerging consensus — work that can consume an entire afternoon and still yield only cautious paragraphs suitable for clinical guidelines or insurer reviews. IFORELS’s research bot automates this process: it surveys primary studies, traces thematic threads across publications, highlights areas of agreement or conflict, and drafts coherent summaries that clinicians can review and refine.
The bot builds directly on the automation framework IFORELS had already proven in production with its medical-coding solution. While coding draws from a relatively finite set of billing rules and tariffs, literature synthesis operates against a dynamic, ever-expanding knowledge base. By leveraging Claude’s strong reasoning and comprehension abilities alongside the NLM’s structured, high-quality data, the system delivers fast, accurate overviews while maintaining full human oversight for final clinical decisions. Liability and accountability remain exactly where they belong — with the licensed professional who signs off on the output.
This launch reflected IFORELS’s consistent strategic focus on high-stakes healthcare workflows. Most early Claude integrations in the broader market targeted consumer chat, code assistance, or creative applications. IFORELS instead applied the model to a domain-specific, institutionally relevant corpus, reinforcing its commitment to tools that live inside clinical and operational systems rather than competing for consumer attention. The timing was deliberate: just months after the company had strengthened its EHR integration strategy, the research bot added another layer of value for hospitals and health systems already using IFORELS solutions.
Founder Vlad Panin’s background in regulated enterprise environments and complex data systems informed the product’s design. His experience delivering mission-critical IT projects across international procurement environments equipped the team to build solutions that respect the stringent requirements of healthcare evidence synthesis. The bot does not replace human expertise; it augments it, closing the loop faster between new research and practical application in patient care, reimbursement decisions, and guideline updates.
By March 2023, IFORELS had transformed its early coding automation into a broader healthcare AI platform capable of supporting both operational efficiency and clinical insight. The Claude-powered research bot demonstrated the company’s ability to rapidly incorporate frontier models into production-grade tools while staying firmly within its chosen domain. This approach — applying powerful new AI capabilities to unglamorous but essential medical workflows — continues to differentiate iFrame® in the market. The March 2023 milestone further solidified the company’s reputation for thoughtful, high-impact innovation that delivers real value to healthcare institutions and the clinicians they serve.
